Related Experiment Video
Updated: Feb 11, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
[The place of immunotherapy in plasma cell myeloma treatment]
Plasma cell myeloma is the second most common haematological malignancy. The therapy in this disease has changed dramatically in recent twenty years due to new drugs implementation such as proteasome inhibitors and immunomodulatory drugs. Scientists’ efforts made to better cognition of normal immune surveillance in myeloma led to the formulation of new treatment strategy including immune system involvement. Many of these therapies are being evaluated in clinical trials and the preliminary results are promising. Probably another time in the last year’s we may witness paradigm revision in the plasma cell myeloma therapy. In the article we present essential, in our opinion, immunotherapy methods in myeloma.
Plasma cell myeloma is the second most common haematological malignancy. The therapy in this disease has changed dramatically in recent twenty years due to new drugs implementation such as proteasome inhibitors and immunomodulatory drugs. Scientists’ efforts made to better cognition of normal immune surveillance in myeloma led to the formulation of new treatment strategy including immune system involvement. Many of these therapies are being evaluated in clinical trials and the preliminary results are promising. Probably another time in the last year’s we may witness paradigm revision in the plasma cell myeloma therapy. In the article we present essential, in our opinion, immunotherapy methods in myeloma.
Related Concept Videos
Tumor Immunotherapy
Protein Buffers in Blood Plasma and Cells
Certain amino acids can exist in a zwitterion state at a...
Composition of Blood Plasma
Enlargement of the Plasma Membrane
Plasma Membrane in Bacteria and Archaea
Drug Distribution: Plasma Protein Binding

